* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Coagulation
		                    
		                    
								Survey							
                            
		                
		                
                            
                            
								Document related concepts							
                        
                        
                    
						
						
							Transcript						
					
					FUNCTIONS OF THE COAGULATION SYSTEM ACTION DESIRED RESULT Rapid formation of mechanically sound clot Stop bleeding quickly Prevent clot formation at non-injured sites Prevent thrombosis Gradual replacement of clot with viable tissue Wound healing BLOOD COAGULATION Platelet plug Fibrin clot PLATELETS WHAT PLATELETS DO  Stick to damaged blood vessels • requires von Willebrand factor  Spread out to cover damaged area  Activate and release contents • partly blocked by aspirin  Aggregate  Cause blood vessel constriction  Cause retraction of clot to draw wound edges together VWF IS A VERY LARGE PROTEIN ELECTRON MICROSCOPIC IMAGES OF SINGLE MOLECULES VWF UNFOLDS UNDER SHEAR STRESS The faster the blood flow, the stickier it gets WHAT PLATELETS DO (2) PLATELET ADHESION TO AREA OF VESSEL INJURY PLATELET SPREADING Patel et al, Blood 2003;101:929-36 PLATELET AGGREGATION FIBRIN CLOT FORMATION  Tissue damage exposes blood to tissue factor  Coagulation cascade: series of enzymatic reactions leading to thrombin formation • takes place mainly on membrane surface, eg platelet membrane  Thrombin converts fibrinogen to fibrin  Fibrin polymerizes and becomes crosslinked Red blood cells trapped in a fibrin mesh TISSUE FACTOR INITIATES FIBRIN CLOT FORMATION  Ubiquitous lipoprotein (part of cell membrane)  Initiates physiologic clotting process  Highest concentration in brain, mucous membranes, skin, and immediately outside blood vessels  Forms "hemostatic envelope"  Not normally found on endothelial cells lining blood vessels, or on circulating blood cells TISSUE FACTOR: THE HEMOSTATIC ENVELOPE Am J Pathol 1989; 134:1087-97 LARGE VESSEL SMALL VESSEL VITAMIN K IS NEEDED FOR PRODUCTION OF SEVERAL CLOTTING PROTEINS  Fat-soluble vitamin present in many foods  Some made by bacteria in gut  Necessary for synthesis of several components of coagulation cascade  Deficiency may lead to low levels of clotting factors, causing a bleeding tendency  Warfarin (Coumadin™): a drug that interferes with vitamin K action • used as an anticoagulant (prevent thrombosis) Production of thrombin Proenzyme (prothrombin) Enzyme Helper Phospholipid membrane Vitamin K necessary to create these specialized binding regions THROMBIN CONVERTS FIBRINOGEN TO FIBRIN Fibrinogen Thrombin Fibrin FIBRIN FORMS LARGE POLYMERS Red blood cells trapped in a fibrin mesh Platelet-fibrin clot Platelets Fibrin FIBRINOLYSIS  Degradation of fibrin clot by enzyme called plasmin  Necessary to remove clot so wound healing can proceed  Plasminogen activators from blood vessels and other cells convert plasminogen to plasmin to begin the process FIBRINOLYSIS Intact fibrin clot Fibrin clot exposed to plasmin REGULATION OF COAGULATION CONFINES CLOT TO INJURED AREA HELPS PREVENT THROMBOSIS  Antithrombin: inhibits thrombin and other enzymes  Protein C: degrades activated factors V and VIII  Protein S: cofactor for protein C  Deficiency of any of these proteins can increase risk of thrombosis DISEASES OF PLATELETS  Thrombocytopenia = low platelet count (may cause bleeding) • decreased production: bone marrow failure, leukemia • increased consumption • autoimmune (ITP) • disseminated intravascular coagulation • microangiopathy • enlarged spleen - sequesters (soaks up) platelets from the bloodstream  Thrombocytosis = high platelet count • myeloproliferative disorders (may cause thrombosis) • inflammation, iron deficiency  Platelet dysfunction • drugs (eg, aspirin) BLEEDING TAKES LONGER TO STOP WHEN THE PLATELET COUNT IS LOW Lower platelets Prolonged bleeding when count < 100K Longer bleeding time ACUTE IMMUNE THROMBOCYTOPENIC PURPURA (ITP) Mainly in children Often associated with viral infection 1. Antigen (virus?) sticks to platelet 2. Antibody in blood sticks to antigen on platelet surface 3. Macrophages (immune cells in spleen, elsewhere) consume antibody-coated platelets 4. Platelet number in blood drops 5. Platelet count usually returns to normal when infection resolves CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA (ITP) Mainly in adults 1. Immune system makes antibody against molecule on platelet surface (auto-antibody) 2. Antibody sticks to platelet 3. Macrophages (immune cells in spleen, elsewhere) ingest antibody-coated platelets 4. Platelet number in blood drops 5. Often chronic, treated with immune suppression or splenectomy Childhood (acute) ITP Usually goes away when virus eliminated Adult (chronic) ITP Does not go away on its own; usually requires immune suppressive medication or splenectomy PURPURA IN ITP PETECHIAE IN ITP INHERITED BLEEDING DISORDERS decreased production of single clotting factor  Hemophilia: complete absence of factor VIII (hemophilia A) or factor IX (hemophilia B) • sex-linked inheritance (99.99% of patients male) • moderate or severe bleeding  von Willebrand disease: partial absence of von Willebrand factor • dominant inheritance • mild or moderate bleeding ACUTE COMPLICATIONS OF HEMOPHILIA Hematoma Hemarthrosis (joint bleeding) LONG-TERM COMPLICATIONS OF HEMOPHILIA Joint destruction Nerve damage ACQUIRED BLEEDING DISORDERS partial absence of several clotting factors  Liver disease  Vitamin K deficiency  Disseminated Intravascular Coagulation & fibrinolysis (DIC)  Anticoagulant drugs: warfarin or heparin  Thrombolytic drugs (plasminogen activators) VITAMIN K DEFICIENCY  Newborn/premature infants  Poor intake  Defective absorption • generalized malabsorption • biliary disease  Diminished production by bacteria in gut (antibiotic treatment)  Vitamin K antagonists • warfarin (Coumadin) • certain antibiotics DISSEMINATED INTRAVASCULAR COAGULATION  Associated with many serious/lifethreatening diseases  Circulating blood exposed to excessive amount of tissue factor or other procoagulant  Breakdown of normal regulatory processes  Formation of circulating (soluble) fibrin  Consumption of clotting proteins and platelets  Accelerated fibrinolysis – clots break down too quickly  Bleeding and/or intravascular clotting in severe cases DIC Soluble fibrin in the blood MONKEY (E. COLI INJECTION) HUMAN (ACUTE LEUKEMIA) TISSUE INJURY IN DIC ASSOCIATED WITH SEPSIS NEJM 2001;344:1593 THROMBOSIS  Venous thrombosis • Blockage of blood return and associated inflammation causes swelling, pain • May become chronic • If clot is dislodged from vein can travel to right ventricle and then lungs (pulmonary embolism)  Arterial thrombosis • Clot prevents inflow of blood, causing ischemic tissue damage or death (infarction) • Examples: myocardial infarction, stroke DEEP VENOUS THROMBOSIS PULMONARY EMBOLISM Arrow points to large clot in pulmonary artery Clot dissolved after administration of fibrinolytic drug CAUSES OF THROMBOSIS  Abnormal or damaged blood vessels  Stasis of blood  Inherited lack of protein which regulates coagulation • antithrombin, protein C, protein S  Resistance to effect of regulatory protein • Factor V "Leiden" = mutation causing resistance to protein C; found in approx 5% of US population  Too many red cells or platelets (thick blood) • polycythemia, thrombocythemia  Thrombosis most likely when several factors present at once
 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
                                             
                                             
                                             
                                             
                                             
                                             
                                             
                                             
                                             
                                             
                                            